Opdivo+Yervoy is similar to Keytruda+Inlyta!

In patients with metastatic RCC with poor performance status (PS≥2), there was no significant difference in ORR, PFS, and OS between the two regimens as first-line therapy

According to the results of a study presented recently at the 2022 American Society of Clinical Oncology Genitourinary Cancer Symposium (ASCO GU), the "dual immunization" regimen Opdivo (nivolumab, nivolumab) + Yervoy (ipilimumab, ipilimumab) Muma) and the "immune + targeting" regimen Keytruda (pembrolizumab, pembrolizumab) + Inlyta (axitinib, axitinib) first-line treatment of metastatic renal cell carcinoma with poor performance status (poor PS) (mRCC) patients, there were no significant differences in overall response rate (ORR), progression-free survival (PFS), and overall survival (OS)

Because patients with poor performance status (PS ≥ 2 points) are often excluded from trials analyzing new standards of mRCC treatment, this study assessed the efficacy and safety of immune checkpoint combination therapy in this group of patients

A total of 56 patients with PS≥2 mRCC who received OY (n=36) or KI (n=20) were included in the analysis

The results showed that the ORR of the whole cohort, OY treatment cohort, and KI treatment cohort were 27%, 20%, and 42%, respectively

The median PFS for the entire cohort was 4.

The analysis also showed that there was no significant difference in OS and PFS between the 2 cohorts according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk score (P=0.

However, prospective real-world studies are needed to confirm these findings